Mesulergine

Mesulergine
Clinical data
Other names	CU-32085
Identifiers
	show IUPAC name
CAS Number	64795-35-3 ;
PubChem CID	68848;
IUPHAR/BPS	206; [3H]mesulergine: 232;
ChemSpider	62081 ;
UNII	SML95FK06I;
ChEBI	CHEBI:73378 ;
ChEMBL	ChEMBL462903 ;
CompTox Dashboard (EPA)	DTXSID3046324 ;
Chemical and physical data
Formula	C18H26N4O2S
Molar mass	362.49 g·mol−1
3D model (JSmol)	Interactive image;
	show SMILES
	show InChI
	(what is this?)

Mesulergine (INN) (developmental code name CU-32085) is a drug of the ergoline group which was never marketed.^[1]^[2] It acts on serotonin and dopamine receptors.^[3]^[4] Specifically, it is an agonist of dopamine D₂-like receptors and serotonin 5-HT₆ receptors and an antagonist of serotonin 5-HT_2A, 5-HT_2B, 5-HT_2C, and 5-HT₇ receptors.^{[citation needed]} It also has affinity for the 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT_1F, and 5-HT_5A receptors.^[5] The compound had entered clinical trials for the treatment of Parkinson's disease; however, further development was halted due to adverse histological abnormalities in rats.^[6] It was also investigated for the treatment of hyperprolactinemia (high prolactin levels).^[7]

References[]

^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 776–. ISBN 978-1-4757-2085-3.
^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–. ISBN 978-94-011-4439-1.
^ Closse A (May 1983). "[³H]Mesulergine, a selective ligand for serotonin-2 receptors". Life Sci. 32 (21): 2485–95. doi:10.1016/0024-3205(83)90375-2. PMID 6855451.
^ Markstein R (November 1983). "Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors". Eur. J. Pharmacol. 95 (1–2): 101–7. doi:10.1016/0014-2999(83)90272-8. PMID 6230246.
^ National Institute of Mental Health. PDSD Ki Database (Internet). ChapelHill (NC): University of North Carolina. Available from: "Archived copy". Archived from the original on 12 April 2021.CS1 maint: archived copy as title (link)
^ Dupont E, Mikkelsen B, Jakobsen J (April 1986). "Mesulergine in early Parkinson's disease: a double blind controlled trial". J. Neurol. Neurosurg. Psychiatry. 49 (4): 390–5. doi:10.1136/jnnp.49.4.390. PMC 1028763. PMID 3517235.
^ Bankowski BJ, Zacur HA (June 2003). "Dopamine agonist therapy for hyperprolactinemia". Clin Obstet Gynecol. 46 (2): 349–62. doi:10.1097/00003081-200306000-00013. PMID 12808385.

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[Elks2014-1] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 776–. ISBN 978-1-4757-2085-3.

[MortonHall2012-2] I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–. ISBN 978-94-011-4439-1.

[pmid6855451-3] Closse A (May 1983). "[³H]Mesulergine, a selective ligand for serotonin-2 receptors". Life Sci. 32 (21): 2485–95. doi:10.1016/0024-3205(83)90375-2. PMID 6855451.

[pmid6230246-4] Markstein R (November 1983). "Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors". Eur. J. Pharmacol. 95 (1–2): 101–7. doi:10.1016/0014-2999(83)90272-8. PMID 6230246.

[PDSDKiDB-5] National Institute of Mental Health. PDSD Ki Database (Internet). ChapelHill (NC): University of North Carolina. Available from: "Archived copy". Archived from the original on 12 April 2021.CS1 maint: archived copy as title (link)

[pmid3517235-6] Dupont E, Mikkelsen B, Jakobsen J (April 1986). "Mesulergine in early Parkinson's disease: a double blind controlled trial". J. Neurol. Neurosurg. Psychiatry. 49 (4): 390–5. doi:10.1136/jnnp.49.4.390. PMC 1028763. PMID 3517235.

[pmid12808385-7] Bankowski BJ, Zacur HA (June 2003). "Dopamine agonist therapy for hyperprolactinemia". Clin Obstet Gynecol. 46 (2): 349–62. doi:10.1097/00003081-200306000-00013. PMID 12808385.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

show v t Ergolines
Lysergic acid derivatives	2-Bromo-LSD (BOL-148) Amesergide Bromocriptine Cabergoline Dihydroergocornine Dihydroergocristine Dihydroergocryptine (Dihydroergonovine, Dihydroergobasine) Dihydroergotamine Epicriptine Ergine (LSA; LA-111; Lysergamide) Ergocornine Ergocristine Ergocryptine Ergoloid (Dihydroergotoxine) Ergometrine (Ergonovine, Ergobasine) Ergometrinine Ergostine Ergotamine Ergotoxine Ergovaline Lisuride LY-215,840 LSH Lysergic acid Lysergic acid methyl ester Lysergol Mesulergine Metergoline MIPLA Methysergide Sergolexole
Psychedelic lysergamides	1B-LSD 1cP-LSD 1P-ETH-LAD 1P-LSD AL-LAD ALD-52 BU-LAD Diallyllysergamide (DAL) Dimethyllysergamide (DAM-57) ECPLA Ergonovine ETFELA ETH-LAD IP-LAD LAE-32 LSD LPD-824 LSM-775 LSH LSD-Pip Lysergic Acid 2-Butylamide Lysergic Acid 2,4-Dimethylazetidide Lysergic Acid 3-Pentylamide Methylergometrine (Methylergonovine, Methylergobasine) MIPLA MLD-41 PARGY-LAD PRO-LAD
Clavines	9-Deacetoxyfumigaclavine C Agroclavine Chanoclavine Chanoclavine II Costaclavin Cycloclavine Elymoclavine Epoxyagroclavine Festuclavine Fumigaclavine A Fumigaclavine B Fumigaclavine C Paliclavine Penniclavine Setoclavine
Other ergolines	Acetergamine CY-208,243 Ergoline Lergotrile Nicergoline Pergolide
Natural sources	Achnatherum robustum (Sleepy Grass) Claviceps spp. (Ergot) Morning glory: Argyreia nervosa (Hawaiian Baby Woodrose), Ipomoea spp.(Morning Glory, Tlitliltzin, Badoh Negro), Rivea corymbosa (Coaxihuitl, Ololiúqui)